Evidence map›Paper›PMID 37020263›Full record

Observational studyBMC gastroenterology2023

Early symptoms preceding post-infectious irritable bowel syndrome following COVID-19: a retrospective observational study incorporating daily gastrointestinal symptoms.

Ryo Yamamoto, Asako Yamamoto, Tatsuhiro Masaoka, Koichiro Homma, Tadashi Matsuoka, Ryo Takemura, Michihiko Wada, Junichi Sasaki, Keio Donner Project

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Post-COVID-19 irritable bowel syndrome: an integrative review.Revista do Colegio Brasileiro de Cirurgioes · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ryo YamamotoDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan.
Asako YamamotoClinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Tatsuhiro MasaokaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. masaoka@keio.jp.
Koichiro HommaDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan.
Tadashi MatsuokaDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan.
Ryo TakemuraClinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Michihiko WadaClinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Junichi SasakiDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan.
Keio Donner Project
Keio University · JPKeio University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntestinal microinflammation with immune dysfunction due to severe acute respiratory syndrome coronavirus 2 reportedly precipitates post-infectious irritable bowel syndrome. This study aimed to elucidate potential risk factors for subsequent development of irritable bowel syndrome, hypothesizing that it is associated with specific symptoms or patient backgrounds.

methodsThis single-center retrospective observational study (2020-2021) included adults with confirmed coronavirus disease requiring hospital admission and was conducted using real-world data retrieved from a hospital information system. Patient characteristics and detailed gastrointestinal symptoms were obtained and compared between patients with and without coronavirus disease-induced irritable bowel syndrome. Multivariate logistic models were used to validate the risk of developing irritable bowel syndrome. Moreover, daily gastrointestinal symptoms during hospitalization were examined in patients with irritable bowel syndrome.

resultsAmong the 571 eligible patients, 12 (2.1%) were diagnosed with irritable bowel syndrome following coronavirus disease. While nausea and diarrhea during hospitalization, elevated white blood cell count on admission, and intensive care unit admission were associated with the development of irritable bowel syndrome, nausea and diarrhea were identified as risk factors for its development following coronavirus disease, as revealed by the adjusted analyses (odds ratio, 4.00 [1.01-15.84] and 5.64 [1.21-26.31], respectively). Half of the patients with irritable bowel syndrome had both diarrhea and constipation until discharge, and constipation was frequently followed by diarrhea.

conclusionsWhile irritable bowel syndrome was rarely diagnosed following coronavirus disease, nausea and diarrhea during hospitalization precede the early signs of irritable bowel syndrome following coronavirus disease.

Indexed as

COVID-19Gastrointestinal DiseasesIrritable Bowel SyndromeAdultConstipationDiarrheaHumansNauseaCOVID-19DiarrheaIrritable bowel syndrome

Identifiers

PMID37020263
PMCPMC10075174
OpenAlexW4362607059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.